ATE504303T1 - Kombination aus roscovitine und cs-682 oder seinem metaboliten cndac - Google Patents

Kombination aus roscovitine und cs-682 oder seinem metaboliten cndac

Info

Publication number
ATE504303T1
ATE504303T1 AT04805910T AT04805910T ATE504303T1 AT E504303 T1 ATE504303 T1 AT E504303T1 AT 04805910 T AT04805910 T AT 04805910T AT 04805910 T AT04805910 T AT 04805910T AT E504303 T1 ATE504303 T1 AT E504303T1
Authority
AT
Austria
Prior art keywords
metabolite
combination
pentofuranosyl
arabino
dioxy
Prior art date
Application number
AT04805910T
Other languages
English (en)
Inventor
Simon Green
Roger Sleigh
Original Assignee
Cyclacel Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cyclacel Ltd filed Critical Cyclacel Ltd
Application granted granted Critical
Publication of ATE504303T1 publication Critical patent/ATE504303T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
AT04805910T 2003-12-04 2004-12-03 Kombination aus roscovitine und cs-682 oder seinem metaboliten cndac ATE504303T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0328180.5A GB0328180D0 (en) 2003-12-04 2003-12-04 Combination
PCT/GB2004/005081 WO2005053699A1 (en) 2003-12-04 2004-12-03 Combination of a cdk inhibitor and cs-682 or a metabolite thereof

Publications (1)

Publication Number Publication Date
ATE504303T1 true ATE504303T1 (de) 2011-04-15

Family

ID=29764611

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04805910T ATE504303T1 (de) 2003-12-04 2004-12-03 Kombination aus roscovitine und cs-682 oder seinem metaboliten cndac

Country Status (10)

Country Link
US (1) US7772207B2 (de)
EP (1) EP1711185B1 (de)
JP (1) JP4778910B2 (de)
AT (1) ATE504303T1 (de)
DE (1) DE602004032178D1 (de)
DK (1) DK1711185T3 (de)
ES (1) ES2361550T3 (de)
GB (1) GB0328180D0 (de)
PT (1) PT1711185E (de)
WO (1) WO2005053699A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0012528D0 (en) * 2000-05-23 2000-07-12 Univ Palackeho Triterpenoid derivatives
US20050072118A1 (en) 2003-10-03 2005-04-07 Griggs Samuel D. Netting chutes with ribbed flooring for manual and/or automated clipping packaging apparatus
GB0226583D0 (en) * 2002-11-14 2002-12-18 Cyclacel Ltd Compounds
GB0229581D0 (en) * 2002-12-19 2003-01-22 Cyclacel Ltd Use
GB0523041D0 (en) * 2005-11-11 2005-12-21 Cyclacel Ltd Combination
GB0609530D0 (en) * 2006-05-12 2006-06-21 Cyclacel Ltd Combination
GB0625283D0 (en) * 2006-12-19 2007-01-24 Cyclacel Ltd Combination
US7863255B2 (en) * 2008-04-29 2011-01-04 Taiho Pharmaceutical Co., Ltd. Methods of administering antitumor agent comprising deoxycytidine derivative
CN102088969B (zh) * 2008-06-09 2013-06-12 西克拉塞尔有限公司 沙帕他滨或cndac与dna甲基转移酶抑制剂如地西他滨和普鲁卡因的组合
EP2696878B1 (de) 2011-04-14 2019-07-10 Cyclacel Limited Dosierungsschema für sapacitabin und decitabin in kombination zur behandlung von akuter myeloischer leukämie
TW201300105A (zh) 2011-05-31 2013-01-01 Piramal Life Sciences Ltd 治療頭頸鱗狀細胞癌之相乘藥物組合物
JP6286421B2 (ja) * 2012-05-15 2018-02-28 サイクラセル リミテッド サパシタビン及びセリシクリブの投与レジメン
CA2917742C (en) 2013-07-12 2020-04-14 Piramal Enterprises Limited A pharmaceutical combination for the treatment of melanoma
WO2021079129A1 (en) 2019-10-24 2021-04-29 Cyclacel Limited Dosing regimen

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2085557C1 (ru) * 1991-09-30 1997-07-27 Санкио Компани Лимитед Производные нуклеозидов пиримидина или их фармацевтически приемлемые соли и способ их получения
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
AU2002228849A1 (en) * 2000-12-08 2002-06-18 Bristol-Myers Squibb Pharma Company Semicarbazides and their uses as cyclin dependent kinase inhibitors
WO2003039536A1 (en) * 2001-11-07 2003-05-15 Yale University Enhancement of taxane-based chemotherapy by a cdk1 antagonist
EP1485168A1 (de) * 2002-03-15 2004-12-15 Cyclacel Limited Kombination eines cdk inhibitors und eines 5-fu zur behandlung von krebs
EP1487495A1 (de) * 2002-03-27 2004-12-22 Cyclacel Limited Kombination enthaltend einen cdk inhibitor und doxorubicin

Also Published As

Publication number Publication date
PT1711185E (pt) 2011-05-12
EP1711185B1 (de) 2011-04-06
EP1711185A1 (de) 2006-10-18
GB0328180D0 (en) 2004-01-07
JP4778910B2 (ja) 2011-09-21
WO2005053699A1 (en) 2005-06-16
DE602004032178D1 (de) 2011-05-19
US7772207B2 (en) 2010-08-10
DK1711185T3 (da) 2011-06-14
JP2007513132A (ja) 2007-05-24
US20070270442A1 (en) 2007-11-22
ES2361550T3 (es) 2011-06-20

Similar Documents

Publication Publication Date Title
MXPA05004919A (es) Composicion farmaceutica que comprende un inhibidor cdk y gemcitabina.
WO2009150405A8 (en) Combinations of sapacitabine or cndac with dna methyltransferase inhibitors such as decitabine and procaine
ATE504303T1 (de) Kombination aus roscovitine und cs-682 oder seinem metaboliten cndac
CY1112889T1 (el) Αναλογα αζετιδινης αναστολεων νουκλεοσιδασης και φωσφορυλασης
DE602005018043D1 (de) Liposomale formulierungen mit dihydrosphingomyelin und verfahren zu ihrer verwendung
ATE498395T1 (de) Allgemein lineare brauseform von fentanyl zur oralen anwendung und verfahren zur verabreichung
IL175568A (en) Tyrosine kinase inhibitors, containing them containing herbal remedies and their use in the preparation of a drug for the treatment of diseases
EA200602241A1 (ru) Замещённые индазолы, композиции, содержащие указанные индазолы, способ их получения и применение
CY1106386T1 (el) Υποκατεστημενα παραγωγα 3-πυρρολιδιν-ινδολης
TW200510375A (en) New compounds
IL220480A0 (en) 1-benzyl-pyrimidine-2,4-dione derivatives as dipeptidyl peptidase inhibitors , preparation method thereof, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments
BRPI0418213A (pt) forma de dosagem, e, método para tratar dor em um paciente em necessidade do mesmo
NO20055204D0 (no) Derivater av piperidinyl- og pipemzinylalkylkarbamater, fremgangsmater for fremstilling derav og anvendelse av de samme i terapi
EA200602047A1 (ru) Сульфонилэтилфосфородиамидаты, предназначенные для применения при лечении рака
WO2007035963A3 (en) Anti-tumor methods using multi drug resistance independent synthetic hsp90 inhibitors
CY1113116T1 (el) Υποκατεστημενες 4-αμινοκυκλοεξανολες
IL179206A0 (en) Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same
MX2009004017A (es) Usos de los compuestos carboxi-amido triazol y sus sales.
AR065581A1 (es) Mejoras en composiciones medicinales o relativas a las mismas
ATE356994T1 (de) Screeningverfahren mit pim1-kinase oder pim3- kinase
ATE523200T1 (de) Kombination mit sapacitibin (2'-cyano-2'-desoxy- n4-palmitoyl-1-beta-d-arabinofuranosyl-cytosin) und einem zytotoxischen mittel
NO20051261L (no) Morfin-6-glukuronidsalt
NO345056B1 (no) Farmasøytisk sammensetning til bruk i en metode for behandling av en depressiv lidelse
ATE418333T1 (de) Kombination aus docetaxel und einem cdk-hemmer
SE0300457D0 (sv) Novel compounds

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1711185

Country of ref document: EP